Pancreatic Cancer Research

ResearcherVita-Salute San Raffaele UniversityActive in the last 2 years

Paolo Giorgio Arcidiacono

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6692-7720; OpenAlex author ID A5082270662. Sources: ClinicalTrials.gov.

Their work

Papers
64 (first author 7, last author 9)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
2
Collaborators
160
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 7 papers · 2021: 8 papers, 1 trial · 2022: 6 papers · 2023: 10 papers · 2024: 6 papers · 2025: 7 papers · 2026: 8 papers

Papers 50 of 64

  1. Presumed Intraductal Papillary Mucinous Neoplasms in Individuals at High Risk for Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2026.35610↗
  2. Paired Duodenal and Salivary Microbiome Analysis in Pancreatic Cancer Without Duct Obstruction. Co-author DOI 10.1002/ueg2.70179↗
  3. Discovering Hereditary Risk Through Surveillance: A Prospective Genetic Analysis of Individuals With Familial Pancreatic Cancer. Co-author DOI 10.1002/ueg2.70187↗
  4. Impact of nutritional status on chemotherapy delivery and outcomes in advanced pancreatic cancer: A prospective multicenter study. Co-author DOI 10.1016/j.clnu.2025.106573↗
  5. Novel approaches to liquid biopsy in pancreatic cancer. Co-author DOI 10.1016/j.dld.2026.06.008↗
  6. Impact of center-level protocol adherence on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2026.117033↗
  7. Glucagon-like Peptide-1 receptor agonists are not associated with increased risk of pancreatic cancer: A systematic review and meta-analysis. First author DOI 10.1016/j.pan.2026.04.005↗
  8. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  9. Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional… Co-author DOI 10.1002/ijc.35196↗
  10. Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer. Co-author DOI 10.1016/j.dld.2024.05.017↗
  11. Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. Co-author DOI 10.1016/j.dld.2025.03.009↗
  12. Author's Reply: Comment on "Association of Smoking with progression from low-risk to high-risk intraductal papillary mucinous neoplasms and pancreatic cancer". First author DOI 10.1016/j.dld.2025.06.006↗
  13. Author's reply: "Comment on "Diagnostic delay at diagnosis and time-to-treatment influence overall survival of pancreatic cancer patients. First author DOI 10.1016/j.dld.2025.08.085↗
  14. Gastrointestinal symptoms in the journey of pancreatic cancer patients. Co-author DOI 10.1080/14737140.2025.2517888↗
  15. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  16. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  17. Communication, understanding and engagement of patients with pancreatic cancer at time of diagnosis. Co-author DOI 10.1016/j.pan.2024.02.008↗
  18. An alternative splicing signature defines the basal-like phenotype and predicts worse clinical outcome in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2024.101411↗
  19. Surveillance of Individuals at High Risk of Developing Pancreatic Cancer: A Prevalence Meta-analysis to Estimate the Rate of Low-yield Surgery. Co-author DOI 10.1097/sla.0000000000006094↗
  20. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  21. Outcomes of a 3-Year Prospective Surveillance in Individuals at High Risk of Pancreatic Cancer. Co-author DOI 10.14309/ajg.0000000000002546↗
  22. Ex-vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. Last author DOI 10.1002/deo2.152↗
  23. Routine Molecular Profiling in Both Resectable and Unresectable Pancreatic Adenocarcinoma: Relevance of Cytologic Samples. Co-author DOI 10.1016/j.cgh.2022.10.014↗
  24. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  25. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  26. The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.dld.2023.04.015↗
  27. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  28. Polymorphic variants involved in methylation regulation: a strategy to discover risk loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/jmg-2022-108910↗
  29. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  30. Role of pancreatic ductal adenocarcinoma risk factors in intraductal papillary mucinous neoplasm progression. Co-author DOI 10.3389/fonc.2023.1172606↗
  31. Immunomodulatory Effects of Endoscopic Ultrasound-Guided Thermal Ablation in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15143704↗
  32. The impact of nutritional status on pancreatic cancer therapy. Co-author DOI 10.1080/14737140.2022.2026771↗
  33. Proposal for a New Pathologic Prognostic Index After Neoadjuvant Chemotherapy in Pancreatic Ductal Adenocarcinoma (PINC). Co-author DOI 10.1245/s10434-022-11413-7↗
  34. Needle-Tract Seeding of Pancreatic Cancer after EUS-FNA: A Systematic Review of Case Reports and Discussion of Management. Last author DOI 10.3390/cancers14246130↗
  35. Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. Last author DOI 10.3748/wjg.v28.i10.976↗
  36. Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Last author DOI 10.4103/eus-d-21-00111↗
  37. EUS-guided ablation with the HybridTherm Probe as second-line treatment in patients with locally advanced pancreatic ductal adenocarcinoma: A case-control stud… Last author DOI 10.4103/eus-d-21-00200↗
  38. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  39. Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Co-author DOI 10.1038/s41598-021-87130-0↗
  40. Associations between pancreatic expression quantitative traits and risk of pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/carcin/bgab057↗
  41. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  42. [The role of endoscopic ultrasound in diagnosis and staging of pancreatic ductal adenocarcinoma.] First author DOI 10.1701/3525.35126↗
  43. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  44. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  45. Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomi… Last author DOI 10.3390/cancers13184512↗
  46. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00280-020-04047-7↗
  47. Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.dld.2020.01.008↗
  48. Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Last author DOI 10.1055/a-1221-9879↗
  49. B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2020.1794359↗
  50. COMMUNI.CARE (COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer): Study Protocol. Co-author DOI 10.3389/fmed.2020.00134↗

Trials 1

  1. Activation of Biobank Registry for Bilio-pancreatic Diseases Principal investigator NCT06552078↗

Closest collaborators

The 25 strongest of 160 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gabriele Capurso · 34 shared papers, 2019–2026 · strength 6.25
  2. Massimo Falconi · 35 shared papers, 2016–2026 · strength 5.10
  3. Michele Reni · 26 shared papers, 2012–2026 · strength 3.61
  4. Lívia Archibugi · 19 shared papers, 2019–2026 · strength 3.12
  5. Maria Chiara Petrone · 15 shared papers, 2012–2026 · strength 1.93
  6. Ruggero Ponz de Leon Pisani · 7 shared papers, 2022–2026 · strength 1.68
  7. Gaetano Lauri · 6 shared papers, 2023–2026 · strength 1.57
  8. Claudio Doglioni · 13 shared papers, 2016–2024 · strength 1.46
  9. Marina Macchini · 9 shared papers, 2018–2026 · strength 1.44
  10. Matteo Tacelli · 6 shared papers, 2021–2026 · strength 1.37
  11. Stefano Crippa · 9 shared papers, 2017–2026 · strength 1.32
  12. Giulia Orsi · 7 shared papers, 2020–2026 · strength 1.18
  13. Gemma Rossi · 8 shared papers, 2020–2026 · strength 1.15
  14. Gianpaolo Balzano · 11 shared papers, 2012–2023 · strength 1.07
  15. Sabrina Gloria Giulia Testoni · 8 shared papers, 2019–2023 · strength 0.98
  16. Francesco DE COBELLI · 7 shared papers, 2020–2026 · strength 0.96
  17. Giulia Martina Cavestro · 5 shared papers, 2021–2026 · strength 0.95
  18. Domenico Tamburrino · 6 shared papers, 2020–2026 · strength 0.94
  19. Marta Puzzono · 4 shared papers, 2024–2026 · strength 0.86
  20. Giuseppe Vanella · 5 shared papers, 2021–2025 · strength 0.82
  21. Emanuel Della‐Torre · 6 shared papers, 2020–2023 · strength 0.72
  22. Giuseppe Malleo · 4 shared papers, 2024–2026 · strength 0.70
  23. Giulio Belfiori · 4 shared papers, 2023–2026 · strength 0.67
  24. Erica Secchettin · 4 shared papers, 2024–2026 · strength 0.67
  25. Salvatore Paiella · 4 shared papers, 2024–2026 · strength 0.67

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.